$7.19
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 25,258 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Country

ES

CEO

Mr. Jose Ignacio Abia

IPO date

2006

Employees

25,000

ISIN

ES0171996087

Key stats

Open

$7.19

Volume

559.27K

Market cap

$6.22B

Prev. close

$7.29

Impl / hst vl

-

Open interest

$0.00

$7.19

Day’s Range

$7.19

$6.96

52W Range

$9.77

Valuation

50
Valuation score
Fairly Valued
P/E
13.12
P/S
0.73
P/B
1.00
Current ratio
2.47
Debt / Equity
1.64
ROE
7.88%
Gross margin
36.47%
Income growth
-25.70%
FCF growth
-93.26

Jul

9

Dividends

The last payment date was Jul 9, 2026

Div. per Share

$0.11

Div. Yield

1.29%

Payout Ratio

-

Div. Growth YoY

-83.33%

Analysts estimates

Consensus rating
Buy

The average rating from top 9 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$12.04
The top 19 analysts forecasts that 12-month price may increase by 67.48%, with a low of $7.40 and a high of $18.13
$7.40
Low
$12.04
Avg
$18.13
High
Current price

Earnings

Q1 ‘26 revenue
$1.94B
Q1 ‘26 net income
$83.39M
Revenue
Net income
Previous EPS
-
Estimate EPS
$0.15
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply